Immunoblot analysis supported these results, where CYP17A1 was higher in the PCOS group (2.21 ± 0.14 fold) and significantly decreased after BM-hMSC treatment (1.37 ± 0.12 fold; Fig. 5e, f). This evidence concerns the gene CYP17A1 and polycystic ovary syndrome.